Nanoparticles, Genome Therapy & Antibodies - The Zhou Research Lab at Yale School of Medicine

Transcript

• 00:03My lab is a biomedical
• 00:04engineering lab. Our chemistry and
• 00:06engineering group, and, work on
• 00:09developing a ray of tachology,
• 00:12mainly for,
• 00:13drug delivery to the brain
• 00:15and also for non viral
• 00:16delivery gene therapy.
• 00:18And our biology team,
• 00:20work together with, our engineering
• 00:22team, you know, to apply,
• 00:24this new technology
• 00:26for treatment of selective neurological
• 00:28disease.
• 00:32We focus on developing three
• 00:34major platform technology,
• 00:36you know, for different applications.
• 00:38The first one, is nanoparticles,
• 00:40you know, because we use
• 00:41a lot of nanoparticles. We
• 00:43engineer particles,
• 00:45blood brain barrier, for delivering
• 00:46drugs into the brain for
• 00:47brain cancer or stroke treatment.
• 00:50The second technology we call
• 00:51step engineering,
• 00:52so which we pioneered,
• 00:55the development. And, we are
• 00:56the only group still now,
• 00:58in the world in, working
• 00:59on delivering genome editing therapy
• 01:01for,
• 01:02many new genetic disease. The
• 01:04third topic actually is the
• 01:06antibody, is a new technology,
• 01:07which are the development in
• 01:09the lab. So we are
• 01:10working on, engineering, developing
• 01:13a group of antibodies
• 01:15which can penetrate cells for
• 01:17treatment now, like Parkinson disease
• 01:19or Huntington disease.
• 01:21But on the biology side,
• 01:23we try to use the
• 01:24established, you know, procedural techniques.
• 01:27We don't want to innovate
• 01:29on the biology side because
• 01:30we our major innovation is
• 01:32on technology, you know, development.
• 01:38My goal is that, you
• 01:39know, translate all research into
• 01:41clinical applications.
• 01:42And for example, for step
• 01:44engineering and, our first,
• 01:46genomic team program, we are
• 01:48more to clinical and, translation.
• 01:50And then nanoparticles,
• 01:52we have a program focused
• 01:54on clinical trials in the
• 01:55next two years.
• 01:56And we also anticipate the
• 01:57antibody work will be, applied
• 01:59into, clinical, you know, for
• 02:01disease treatment in the very
• 02:02near future.
• 02:04Most of my work cannot
• 02:05be carried out without, the
• 02:07collaboration,
• 02:09particularly this collaboration with our
• 02:10physician colleagues. For example, for
• 02:12Geelong Medicine,
• 02:14we closely collaborated with Yong
• 02:15Heizhan's group. You know, for
• 02:18antibody, we, closely work with,
• 02:20Professor James Hansen.
• 02:22And then for stroke, you
• 02:23know, we work with, chemo
• 02:24chairs. For brain cancer, we
• 02:26work in a chair monitor.
• 02:28That's actually how make our
• 02:30research unique and, translational.